- Home
- SSSS vs CNTB Comparison
SSSS vs CNTB Comparison
Compare SSSS & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- CNTB
- Stock Information
- Founded
- SSSS 2010
- CNTB 2012
- Country
- SSSS United States
- CNTB United States
- Employees
- SSSS N/A
- CNTB N/A
- Industry
- SSSS Finance: Consumer Services
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- CNTB Health Care
- Exchange
- SSSS Nasdaq
- CNTB Nasdaq
- Market Cap
- SSSS 138.2M
- CNTB 114.8M
- IPO Year
- SSSS N/A
- CNTB 2021
- Fundamental
- Price
- SSSS $9.27
- CNTB $1.57
- Analyst Decision
- SSSS Strong Buy
- CNTB Strong Buy
- Analyst Count
- SSSS 4
- CNTB 2
- Target Price
- SSSS $9.50
- CNTB $7.50
- AVG Volume (30 Days)
- SSSS 253.2K
- CNTB 184.6K
- Earning Date
- SSSS 11-06-2025
- CNTB 09-05-2025
- Dividend Yield
- SSSS 10.75%
- CNTB N/A
- EPS Growth
- SSSS N/A
- CNTB N/A
- EPS
- SSSS 2.22
- CNTB N/A
- Revenue
- SSSS $2,784,381.00
- CNTB $1,965,000.00
- Revenue This Year
- SSSS $6.95
- CNTB N/A
- Revenue Next Year
- SSSS N/A
- CNTB N/A
- P/E Ratio
- SSSS $4.19
- CNTB N/A
- Revenue Growth
- SSSS N/A
- CNTB N/A
- 52 Week Low
- SSSS $3.75
- CNTB $1.56
- 52 Week High
- SSSS $9.34
- CNTB $2.20
- Technical
- Relative Strength Index (RSI)
- SSSS 72.57
- CNTB 39.75
- Support Level
- SSSS $8.63
- CNTB $1.63
- Resistance Level
- SSSS $8.75
- CNTB $1.79
- Average True Range (ATR)
- SSSS 0.15
- CNTB 0.18
- MACD
- SSSS 0.03
- CNTB -0.04
- Stochastic Oscillator
- SSSS 91.78
- CNTB 0.39
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.